Clinical Trial

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
Trial Details
NCT Number NCT06951841
Lead Sponsor China Medical University, China
Conditions Small Cell Lung Cancer
Enrollment 31 participants
Start Date 2025-04-30
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-30